RIPK3 and neoplasm: As has been reported, RIPK3‐mediated phosphoglycerate mutase 5 (PGAM5) activation promoted a NK T‐cell‐mediated antitumor immune response by activating nuclear factor of activated T cells (NFAT) and dephosphorylation of dynamically‐associated protein 1 (Drp1) in a process independent of the necrotic pathway.[1a] In addition, in isogenic melanoma and lung adenocarcinoma models, the injection of necrotic tumor cells activated by RIPK3 into existing tumors enhanced antitumor immunity.